All In Biotech

Drug Trial Radar · NCT07436221

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma

A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK139 in the Treatment of Participants With Moderate to Severe Asthma

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Feb 28, 2026

Primary completion

Dec 27, 2026

Study completion Feb 26, 2027

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe asthma.

Conditions

  • Asthma

Interventions

  • AK139Drug

    AK139 regimen 1- subcutaneous injection.

  • AK139Drug

    AK139 regimen 2- subcutaneous injection.

  • AK139Drug

    AK139 regimen 3- subcutaneous injection.

  • PlaceboDrug

    subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in pre-bronchodilator FEV1Time frame: Up to week 12
  2. Absolute change and percent change from baseline in FENOTime frame: Up to week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

  • Shanghai General Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.